Entry Detail



General Information

Database ID:exR0274696
RNA Name:hsa-miR-301b-3p
RNA Type:miRNA
Chromosome:chr22
Starnd:+
Coordinate:
Start Site(bp):21653025End Site(bp):21653047
External Links:hsa-miR-301b-3p



Disease Information

Disease Name:Breast Cancer
Disease Category:Cancers
MeSH ID:D001943
Type:Neoplasms/Breast Neoplasms
Alias:Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast



Expression Detail

GEO ID:GSE22981
Description:Circulating miRNAs as biomarkers and potential functional mediators of early stage breast cancer
Experimental Design:Cancer vs Control
Case Disease Type:Breast Cancer
Case Disease SubType:Early satge breast cancer
Case Sample:Breast Cancer
Control Sample:Control
Number of Case:20
Number of Control:20
Number of Samples:40





Regulatory Relationship

mRNA targets:NA
miRNA targets:NA
circRNA targets:
circRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
hsa_circ_0000591
chr15
41961025
41962156
+
hsa_circ_0001454
chr4
154524454
154533552
+
hsa_circ_0000384
chr12
27867712
27877119
+
hsa_circ_0001723
chr7
91924202
91948826
+
hsa_circ_0000892
chr19
11941431
12014514
+
hsa_circ_0001605
chr6
42903447
42905047
+
hsa_circ_0000155
chr1
168007608
168014465
+
hsa_circ_0001495
chr5
68470703
68471364
+
hsa_circ_0000943
chr19
47421744
47440665
+
hsa_circ_0000018
chr1
15860731
15863309
+
lncRNA targets:
lncRNA SymbolChromosomeStart Site(bp)End Site(bp)Strand
AC011503.2
chr19
23927788
23929287
+
AC021092.1
chr19
44103007
44113183
-
AC135050.6
chr16
31122235
31124064
+
AC234582.1
chr1
155195004
155205495
+
AL031595.3
chr22
44139365
44153626
+
AL049840.4
chr14
103694516
103695050
-
AL158206.1
chr9
19453209
19455173
+
AL158825.2
chr9
75009828
75016036
-
AL603839.3
chr1
40493157
40508661
-
CKMT2-AS1
chr5
81201341
81301565
-
H19
chr11
1995176
2001470
-
HAGLR
chr2
176164051
176188958
-
KCNQ1OT1
chr11
2608328
2699994
-
LINC01089
chr12
121795267
121803906
-
MIR17HG
chr13
91347820
91354579
+
NEAT1
chr11
65422774
65445540
+
XIST
chrX
73820649
73852723
-
Display:



Experiment Detail

GEO ID:GSE22981
Sample Source:Blood
Source Fraction:Plasma
Platform:GPL8179
Method:Microarray
Num of detected RNA Type:1
Num of detected RNAs of this Type:801
Sample treatment protocol:NA
RNA Extract protocol:Total RNA, including miRNA from plasma, was isolated using the miRNeasy kit (Qiagen) with minor modifications.
RNA library preparation protocol:Two hundred ng of total RNA from each sample were labeled and hybridized on Human v2 MicroRNA Expression BeadChips (Cat. no. MI-102-1024; Illumina).



Reference

PMID:21060830
Title:A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer
Author:Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu SBACKGROUND: To date, there are no highly sensitive and specific minimally invasive biomarkers for detection of breast cancer at an early stage. The occurrence of circulating microRNAs (miRNAs) in blood components (including serum and plasma) has been repeatedly observed in cancer patients as well as healthy controls. Because of the significance of miRNA in carcinogenesis, circulating miRNAs in blood may be unique biomarkers for early and minimally invasive diagnosis of human cancers. The objective of this pilot study was to discover a panel of circulating miRNAs as potential novel breast cancer biomarkers. METHODOLOGY/PRINCIPAL FINDINGS: Using microarray-based expression profiling followed by Real-Time quantitative Polymerase Cycle Reaction (RT-qPCR) validation, we compared the levels of circulating miRNAs in plasma samples from 20 women with early stage breast cancer (10 Caucasian American (CA) and 10 African American (AA)) and 20 matched healthy controls (10 CAs and 10 AAs). Using the significance level of p<0.05 constrained by at least two-fold expression change as selection criteria, we found that 31 miRNAs were differentially expressed in CA study subjects (17 up and 14 down) and 18 miRNAs were differentially expressed in AA study subjects (9 up and 9 down). Interestingly, only 2 differentially expressed miRNAs overlapped between CA and AA study subjects. Using receiver operational curve (ROC) analysis, we show that not only up-regulated but also down-regulated miRNAs can discriminate patients with breast cancer from healthy controls with reasonable sensitivity and specificity. To further explore the potential roles of these circulating miRNAs in breast carcinogenesis, we applied pathway-based bioinformatics exploratory analysis and predicted a number of significantly enriched pathways which are predicted to be regulated by these circulating miRNAs, most of which are involved in critical cell functions, cancer development and progression. CONCLUSIONS: Our observations from this pilot study suggest that the altered levels of circulating miRNAs might have great potential to serve as novel, noninvasive biomarkers for early detection of breast cancer.
Journal:PLoS One. 2010 Oct 29;5(10):e13735.
Description:The objective of this pilot study was to discover a panel of circulating miRNAs as potential novel breast cancer biomarkers.